FSFeifei Sun

Feifei Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Feifei Sun has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Junting Huang

    Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China

    15 shared publications
  • Juan Wang

    Department of Pediatric Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

    10 shared publications
  • Yizhuo Zhang

    Sun Yat-sen University Cancer Center

    10 shared publications
  • Suying Lu

    Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

    9 shared publications
  • Jia Zhu

    Department of Pediatric Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

    8 shared publications
  • Suying Lu

    Department of Pediatric Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

    8 shared publications

Latest Publications

  • Open Access

    AURKB inhibition induces rhabdomyosarcoma apoptosis and ferroptosis through NPM1/SP1/ACSL5 axis

    by Huimou Chen, Mengzhen Li, Yu Zhang, Mengjia Song, Yi Que, Juan Wang, Feifei Sun, Jia Zhu, Junting Huang, Juan Liu, et al.

    Rhabdomyosarcoma (RMS) is one of the most common solid tumors in children and adolescents. Patients with relapsed/refractory RMS have limited treatment options, highlighting the urgency for the identification of novel therapeutic targets for RMS. In the present study, aurora kinase B (AURKB) was found to be highly expressed in RMS and associated with unfavorable prognosis of patients. Functional experiments indicated that inhibition of AURKB significantly reduced RMS cell proliferation, induced apoptosis and ferroptosis, and suppressed RMS growth in vivo. The highly expressed AURKB in RMS contributes to the apoptosis and ferroptosis resistance of tumor cells through the nucleophosmin 1 (NPM1)/Sp1 transcription factor (SP1)/acyl-CoA synthetase long-chain family member 5 (ACSL5) axis. Furthermore, inhibition of AURKB exerted an anti-RMS effect together with vincristine both in vitro and in vivo, with tolerable toxicity. The above findings provide insights we believe are new into the tumorigenesis of RMS, especially with regard to apoptosis or ferroptosis resistance, indicating that AURKB may be a potential target for clinical intervention in patients with RMS.


  • Open Access

    MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma

    by Jinqiu Guan, Mengzhen Li, Yi Wang, Yu Zhang, Yi Que, Suying Lu, Juan Wang, Jia Zhu, Junting Huang, Zijun Zhen, et al.

    MYCN amplification is an independent poor prognostic factor in patients with high-risk neuroblastoma (NB). Further exploring the molecular regulatory mechanisms in MYCN-amplified NB will help to develop novel therapy targets. In this study, methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) was identified as the differentially expressed gene (DEG) highly expressed in MYCN-amplified NB, and it showed a positive correlation with MYCN and was associated with a poor prognosis of NB patients. Knockdown of MTHFD1 inhibited proliferation and migration, and induced apoptosis of NB cells in vitro. Mouse model experiments validated the tumorigenic effect of MTHFD1 in NB in vivo. In terms of the mechanism, ChIP-qPCR and dual-luciferase reporter assays demonstrated that MTHFD1 was directly activated by MYCN at the transcriptional level. As an important enzyme in the folic acid metabolism pathway, MTHFD1 maintained the NADPH redox homeostasis in MYCN-amplified NB. Knockdown of MTHFD1 reduced cellular NADPH/NADP+ and GSH/GSSG ratios, increased cellular reactive oxygen species (ROS) and triggered the apoptosis of NB cells. Moreover, genetic knockdown of MTHFD1 or application of the anti-folic acid metabolism drug methotrexate (MTX) potentiated the anti-tumor effect of JQ1 both in vitro and in vivo. Taken together, MTHFD1 as an oncogene is a potential therapeutic target for MYCN-amplified NB. The combination of MTX with JQ1 is of important clinical translational significance for the treatment of patients with MYCN-amplified NB.


  • Open Access

    The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma

    by Mengzhen Li, Yang Hu, Juan Wang, Yanjie Xu, Ye Hong, Li Zhang, Qiuyun Luo, Zijun Zhen, Suying Lu, Junting Huang, et al.

    Neuroblastoma (NB) is one of the common solid tumors in childhood and poses a threat to the lives of children. Patients with advanced‑stage or recurrent NB have a poor prognosis. CUDC‑907, as a novel dual‑target inhibitor of histone deacetylase (HDAC) and phosphatidylinositol‑3‑kinase (PI3K), has been proven to play an antitumor role in several types of tumors. However, the exact role of CUDC‑907 in NB remains unclear. In the present study, in vivo and in vitro assays were performed to investigate the anti‑NB activity of CUDC‑907. Pentraxin 3 (PTX3) small interfering RNA (siRNA) and PTX3 overexpression plasmid were transfected into cells to define the underlying mechanisms of CUDC‑907. Tumor tissues and clinical information were collected and immunohistochemistry (IHC) was conducted to analyze the association between the expression of HDAC1, HDAC2, HDAC3 and CD44, and the prognosis of patients with NB. The results indicated that CUDC‑907 significantly inhibited the proliferation and migration, and induced the apoptosis of NB cells, downregulating the expression level of MYCN, and suppressing the PI3K/AKT and MAPK/ERK pathways. Furthermore, CUDC‑907 suppressed the stem‑like properties of NB cells by inhibiting PTX3, a ligand and upstream protein of CD44. IHC revealed that the high expression of HDAC1, 2, 3 and CD44 was associated with a poor prognosis of patients with NB. On the whole, these findings indicate that CUDC‑907 may be developed into a possible therapeutic approach for patients with NB.


  • Open Access

    A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis

    by Junting Huang, Suying Lu, Juan Wang, Lian Jiang, Xuequn Luo, Xiangling He, Yanpeng Wu, Yi Wang, Xiuli Zhu, Jian Chen, et al.

    Background: Pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF) can be used in pediatric patients. This study assessed the safety and efficacy of PEG‐rhG‐CSF as a primary prophylactic drug against neutropenia after chemotherapy in pediatric patients with solid tumors or non‐Hodgkin lymphoma (NHL).Patients and Methods: This phase II study (between October 2020 and March 2022) enrolled pediatric patients with solid tumors or NHL treated with high‐intensity chemotherapy and with grade ≥3 myelosuppression for at least 14 days during chemotherapy. Prophylactic PEG‐rhG‐CSF was given at 100 μg/kg body weight (maximum total dosage of 6 mg) once 24–48 h following chemotherapy for two cycles. The primary endpoint was the incidence of PEG‐rhG‐CSF‐related adverse events (AEs). The key secondary endpoints were the rates of grade 3/4 neutropenia and febrile neutropenia (FN).Results: This study included 160 pediatric patients with a median age of 6.22 (0.29, 18.00) years. Fifty‐eight patients (36.25%) were diagnosed with sarcoma. AEs potentially related to PEG‐rhG‐CSF included bone pain (n = 32), fatigue (n = 21), pain at the injection site (n = 21), and myalgia (n = 20). The rates of grade 3/4 neutropenia and FN during treatment were 57.28% and 29.45%, respectively.Conclusion: PEG‐rhG‐CSF is well tolerated and effective in pediatric patients with solid tumors or NHL. These findings should be substantiated with further trials.Clinical Trial Registration: ClinicalTrials.gov identifier: NCT04547829.


  • Open Access

    Dual HDAC and PI3K inhibitor CUDC-907 inhibits tumor growth and stem-like properties via suppressing PTX3 in neuroblastoma.

    by Yang Hu, Mengzhen Li, Juan Wang, Yanjie Xu, Ye Hong, Li Zhang, Qiu-Yun Luo, Zijun Zhen, Suying Lu, Junting Huang, et al.

    Background Neuroblastoma is one of the common solid tumors in childhood and threatens the lives of children. Patients with advanced or recurrent neuroblastoma have a poor prognosis. CUDC-907, as a novel dual-target inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K), has been proved to play an anti-tumor role in several tumors. However, whether CUDC-907 has anti-tumor effect in neuroblastoma is still unclear.Methods In vivo and in vitro assays were performed to investigate the anti-neuroblastoma activity of CUDC-907. PTX3 siRNA-expressing and PTX3 overexpressing plasmid were employed to define the underlying mechanisms of CUDC-907. Tumor tissues and clinical information were collected, and immunohistochemical staining was conducted to analysis the relationship between the expression of HDAC1, HDAC2, HDAC3, CD44 and prognosis of patients with neuroblastoma.Results CUDC-907 significantly inhibits proliferation, migration and promotes apoptosis of neuroblastoma cells, down-regulates the expression level of MYCN, as well as PI3K/AKT and MAPK/ERK pathways. Furthermore, CUDC-907 represses the stem-like properties of neuroblastoma cells via inhibiting PTX3, a ligand and upstream protein of cancer stem marker CD44. Immunohistochemical analysis showed that high expression of HDAC1, 2, 3 and CD44 is associated with poor prognosis of neuroblastoma patients.Conclusions These findings indicate that CUDC-907 might be developed into a possible therapeutic approach for neuroblastoma patients.

  • Open Access

    Immune-Related LncRNAs as Prognostic Factors for Pediatric Rhabdoid Tumor of the Kidney

    by Ye Hong, Yi Que, Yang Hu, Bo-Yun Shi, Jia Zhu, Juan Wang, Jun-Ting Huang, Fei-Fei Sun, Lian Zhang, Xin-Ke Zhou, et al.

    Background. Immune-related long noncoding RNAs (IrlncRNAs) are recognized as important prognostic factors in a variety of cancers, but thus far, their prognostic value in pediatric rhabdoid tumor of the kidney (pRTK) has not been reported. Here, we clarified the associations between IrlncRNAs and overall survival (OS) of pRTK patients and constructed a model to predict their prognosis. Methods. We accessed RNA sequencing data and corresponding clinical data of pRTK from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database. An expression profile of immune-related genes (Irgenes) and lncRNAs of pRTK was extracted from the RNA sequencing data. IrlncRNAs were defined by co-expression analysis of lncRNAs and Irgenes. The limma R package was used to identify differential expression IrlncRNAs. Univariate and multivariate Cox regression analyses were conducted to build a prognostic IrlncRNAs model. The performance of this prognostic model was validated by multimethods, like ROC curve analysis. Results. A total of 1097 IrlncRNAs were defined. Univariate Cox regression analysis identified 7 IrlncRNAs (AC004791.2, AP003068.23, RP11-54O7.14, RP11-680F8.1, TBC1D3P1-DHX40P1, TUNAR, and XXbac-BPG308K3.5) and were significantly associated with OS. Multivariate regression analysis constructed the best prognostic model based on the expression of AC004791.2, AP003068.23, RP11-54O7.14, TBC1D3P1-DHX40P1, and TUNAR. According to the prognostic model, a risk score of each patient was calculated, and patients were divided into high-risk and low-risk groups accordingly. The survival time of low-risk patients was significantly better than high-risk patients ( ). Univariate (hazard ratio 1.098, 95% confidence interval 1.048–1.149, value value Conclusions. The prognostic model based on 5 IrlncRNAs was robust and could better predict the survival of pRTK than other clinical factors. Additionally, the mechanism of regulation and action of prognosis-associated lncRNAs could provide new avenues for basic research to explore the mechanism of tumor initiation and development in order to prevent and treat pRTK.

  • Open Access

    Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies

    by Xiaofei Sun, Zijun Zhen, Ying Guo, Yuanhong Gao, Juan Wang, Yu Zhang, Jia Zhu, Suying Lu, Feifei Sun, Junting Huang, et al.

    Despite aggressive treatment, the prognosis of high-risk NB patients is still poor. This retrospective study investigated the benefits of metronomic maintenance treatment (MT) in high-risk NB patients without ASCT or GD2 antibody therapy. Patients aged ≤ 21 years with newly diagnosed high-risk NB were included. Patients with complete/very good partial remission (CR/VGPR/PR) to conventional treatment received, or not, oral metronomic MT for 1 year. Two hundred and seventeen high-risk NB patients were enrolled. One hundred and eighty-five (85%) had a CR/VGPR/PR to conventional treatment, of the patients with stage 4, 106 receiving and 61 not receiving oral metronomic MT, and the 3-year event-free survival (EFS) rate was 42.5 ± 5.1% and 29.6 ± 6%, respectively (p = 0.017), and overall survival (OS) rate was 71.1 ± 4.7% and 59.4 ± 6.4%, respectively (p = 0.022). A total of 117 high-risk patients with oral metronomic MT had EFS rate of 42.7 ± 4.8%. The toxicity of MT was mild. For high-risk NB patients without ASCT or anti-GD2 antibody therapy, stage 4, MYCN amplication and patients with stage 4 not receiving oral metronomic MT after CR/VGPR/PR were independent adverse prognostic factors. Oral metronomic MT can improve survival in high-risk NB patients in CR/VGPR/PR without ASCT or anti-GD2 antibodies therapy.


  • Open Access

    Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children

    by Jia Zhu, Zijun Zhen, Juan Wang, Feifei Sun, Suying Lu, Junting Huang, Yizhuo Zhang, Xiaofei Sun

    Importance: Burkitt lymphoma with bone marrow involvement and Burkitt leukemia behave aggressively. Thus far, there are limited data concerning survival and toxicity in Chinese children with Burkitt lymphoma or Burkitt leukemia who have undergone treatment with the non‐Hodgkin’s lymphoma Berlin‐Frankfurt‐Münster‐90/95 (NHL‐BFM‐90/95) protocol.Objective: To analyze outcomes and toxicity in pediatric patients who exhibit Burkitt lymphoma with bone marrow involvement or Burkitt leukemia following treatment with the NHL‐BFM‐90/95 protocol.Methods: Patients aged <18 years with bone marrow involvement/leukemia who were treated with the NHL‐BFM‐90/95 protocol, with or without rituximab, in Sun Yat‐Sen University Cancer Center from April 2004 to December 2018 were included in this retrospective analysis.Results: Twenty‐five patients were eligible. Burkitt lymphoma with bone marrow involvement and Burkitt leukemia were present in 10 and 15 patients, respectively. Central nervous system infiltration was not observed in any patients. All patients underwent chemotherapy involving NHL‐BFM‐90/95 protocol. Six courses of treatment were administered to each patient (v‐AA‐BB‐CC‐AA‐BB‐CC). The BFM‐90/95 plus rituximab protocol was administered to 13 patients. The median follow‐up interval was 31.9 months (range, 2.5–158 months). Of the 25 patients, four died: three died of tumor progression and one died of therapy abandonment after relief of tumor lysis syndrome. The estimated 5‐year event‐free survival and overall survival rates were both 85.8% ± 5.0%.Interpretation: Chinese pediatric patients who exhibit Burkitt lymphoma with bone marrow involvement or Burkitt leukemia can achieve optimal treatment outcomes and exhibit good tolerance when using the NHL‐BFM‐90/95 protocol.


  • Open Access

    ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma

    by Mengzhen Li, Chengtao Sun, Xiaoyun Bu, Yi Que, Lian Zhang, Yu Zhang, Li Zhang, Suying Lu, Junting Huang, Jia Zhu, et al.

    Neuroblastoma (NB) is the most common extracranial solid malignancy in children and its mortality rate is relatively high. However, driver genes of NB are not clearly identified. Using bioinformatics analysis, we determined the top 8 differentially expressed genes (DEGs) in NB, including GFAP, PAX6, FOXG1, GAD1, PTPRC, ISL1, GRM5, and GATA3. Insulin gene enhancer binding protein 1 (ISL1) is a LIM homeodomain transcription factor which has been found to be highly expressed in a variety of malignant tumors, but the function of ISL1 in NB has not been fully elucidated. We identified ISL1 as an oncogene in NB. ISL1 is preferentially upregulated in NB tissues compared with normal tissues. High ISL1 expression is significantly associated with poor outcome of NB patients. Knockdown of ISL1 markedly represses proliferation and induces cell apoptosis in vitro, and suppresses tumorigenicity in vivo, while overexpression of ISL1 has the opposite effects. Mechanistically, we demonstrate that ISL1 promotes cell proliferation and EMT transformation through PI3K/AKT signaling pathway by upregulating Aurora kinase A (AURKA), a serine-threonine kinase that is essential for the survival of NB cells. The blockade of AURKA attenuates the function of ISL1 overexpression in the regulation of cell proliferation and migration, Conclusively, this study showed that ISL1 targeted AURKA to facilitate the development of NB, which provided new insights into the tumorigenesis of NB. Thus, ISL1 may be a promising therapeutic target in the future.


  • Venous thromboembolic events in T-cell lymphoma patients: Incidence, risk factors and clinical features

    by Yingxia Lan, Jinqiu Guan, Jia Zhu, Juan Wang, Mengzhen Li, Chengtao Sun, Feifei Sun, Junting Huang, Suying Lu, Yizhuo Zhang